501 related articles for article (PubMed ID: 19417020)
1. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer.
Homma S; Ishii Y; Morishima Y; Yamadori T; Matsuno Y; Haraguchi N; Kikuchi N; Satoh H; Sakamoto T; Hizawa N; Itoh K; Yamamoto M
Clin Cancer Res; 2009 May; 15(10):3423-32. PubMed ID: 19417020
[TBL] [Abstract][Full Text] [Related]
2. Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer.
Ma X; Zhang J; Liu S; Huang Y; Chen B; Wang D
Cancer Chemother Pharmacol; 2012 Feb; 69(2):485-94. PubMed ID: 21842204
[TBL] [Abstract][Full Text] [Related]
3. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance.
Cho JM; Manandhar S; Lee HR; Park HM; Kwak MK
Cancer Lett; 2008 Feb; 260(1-2):96-108. PubMed ID: 18036733
[TBL] [Abstract][Full Text] [Related]
4. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs.
Tang X; Wang H; Fan L; Wu X; Xin A; Ren H; Wang XJ
Free Radic Biol Med; 2011 Jun; 50(11):1599-609. PubMed ID: 21402146
[TBL] [Abstract][Full Text] [Related]
5. The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin.
Li P; Wang K; Zhang J; Zhao L; Liang H; Shao C; Sutherland LC
Cancer Epidemiol; 2012 Oct; 36(5):481-9. PubMed ID: 22609235
[TBL] [Abstract][Full Text] [Related]
6. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
[TBL] [Abstract][Full Text] [Related]
7. [The effect of Bcl-2 gene silencing on the sensitivity of cell line A549 to chemotherapeutic drugs].
Wang JQ; Du ZW; Gao XF; Wu M; Zhang YC; Pan Y; Wang Q; Zhang GZ
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):191-7. PubMed ID: 23856142
[TBL] [Abstract][Full Text] [Related]
8. Suppression of Nrf2-driven heme oxygenase-1 enhances the chemosensitivity of lung cancer A549 cells toward cisplatin.
Kim HR; Kim S; Kim EJ; Park JH; Yang SH; Jeong ET; Park C; Youn MJ; So HS; Park R
Lung Cancer; 2008 Apr; 60(1):47-56. PubMed ID: 18006113
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification.
Chen CC; Chu CB; Liu KJ; Huang CY; Chang JY; Pan WY; Chen HH; Cheng YH; Lee KD; Chen MF; Kuo CC; Chen LT
Biochem Pharmacol; 2013 Oct; 86(7):872-87. PubMed ID: 23933386
[TBL] [Abstract][Full Text] [Related]
10. Enhanced sensitivity of A549 cells to the cytotoxic action of anticancer drugs via suppression of Nrf2 by procyanidins from Cinnamomi Cortex extract.
Ohnuma T; Matsumoto T; Itoi A; Kawana A; Nishiyama T; Ogura K; Hiratsuka A
Biochem Biophys Res Commun; 2011 Oct; 413(4):623-9. PubMed ID: 21925486
[TBL] [Abstract][Full Text] [Related]
11. Cryptotanshinone Reverses Cisplatin Resistance of Human Lung Carcinoma A549 Cells through Down-Regulating Nrf2 Pathway.
Xia C; Bai X; Hou X; Gou X; Wang Y; Zeng H; Huang M; Jin J
Cell Physiol Biochem; 2015; 37(2):816-24. PubMed ID: 26356271
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of PDGFR by CP-673451 induces apoptosis and increases cisplatin cytotoxicity in NSCLC cells via inhibiting the Nrf2-mediated defense mechanism.
Yang Y; Deng Y; Chen X; Zhang J; Chen Y; Li H; Wu Q; Yang Z; Zhang L; Liu B
Toxicol Lett; 2018 Oct; 295():88-98. PubMed ID: 29857117
[TBL] [Abstract][Full Text] [Related]
13. Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway.
Chian S; Zhao Y; Xu M; Yu X; Ke X; Gao R; Yin L
Anticancer Drugs; 2019 Sep; 30(8):838-845. PubMed ID: 31415285
[TBL] [Abstract][Full Text] [Related]
14. Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway.
Wu S; Zhang T; Du J
Drug Des Devel Ther; 2016; 10():3471-3481. PubMed ID: 27822011
[TBL] [Abstract][Full Text] [Related]
15. Decrease in susceptibility toward induction of apoptosis and alteration in G1 checkpoint function as determinants of resistance of human lung cancer cells against the antisignaling drug UCN-01 (7-Hydroxystaurosporine).
Sugiyama K; Akiyama T; Shimizu M; Tamaoki T; Courage C; Gescher A; Akinaga S
Cancer Res; 1999 Sep; 59(17):4406-12. PubMed ID: 10485490
[TBL] [Abstract][Full Text] [Related]
16. Nrf2 inhibition sensitizes cholangiocarcinoma cells to cytotoxic and antiproliferative activities of chemotherapeutic agents.
Samatiwat P; Prawan A; Senggunprai L; Kukongviriyapan U; Kukongviriyapan V
Tumour Biol; 2016 Aug; 37(8):11495-507. PubMed ID: 27015836
[TBL] [Abstract][Full Text] [Related]
17. MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression.
Zang YS; Zhong YF; Fang Z; Li B; An J
Cancer Gene Ther; 2012 Nov; 19(11):773-8. PubMed ID: 22996741
[TBL] [Abstract][Full Text] [Related]
18. A549 cell proliferation inhibited by RNAi mediated silencing of the Nrf2 gene.
Zhang B; Xie C; Zhong J; Chen H; Zhang H; Wang X
Biomed Mater Eng; 2014; 24(6):3905-16. PubMed ID: 25227109
[TBL] [Abstract][Full Text] [Related]
19. Nrf2 mediates the resistance of human A549 and HepG2 cancer cells to boningmycin, a new antitumor antibiotic, in vitro through regulation of glutathione levels.
Zhang HX; Chen Y; Xu R; He QY
Acta Pharmacol Sin; 2018 Oct; 39(10):1661-1669. PubMed ID: 30287928
[TBL] [Abstract][Full Text] [Related]
20. Dickkopf-3 (Dkk3) induces apoptosis in cisplatin-resistant lung adenocarcinoma cells via the Wnt/β-catenin pathway.
Wang Z; Ma LJ; Kang Y; Li X; Zhang XJ
Oncol Rep; 2015 Mar; 33(3):1097-106. PubMed ID: 25573172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
